⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockIsraelNYSE

TEVA

Teva Pharmaceutical Industries Limited

Healthcare · Drug Manufacturers - Specialty & Generic

36.85USD

+0.0900 (+0.24%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.7▲$0.4263
Next quarter$0.74▲$0.7163
Current year$2.14▼$2.3725
Next year$3.07▼$3.136

Recent quarters

Beat in 3 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.11$0.02-0.09 (-81.5%)
2026-03-31$0.46$0.53+0.07 (+16.2%)
2025-12-31$0.64$0.96+0.32 (+50.2%)
2025-09-30$0.67$0.78+0.11 (+15.7%)

Wall Street coverage

275 ratings from 45 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
UBSMaintainedBuy$42 $48Sep 4, 2026
BarclaysMaintainedOverweight$40 $42Aug 12, 2026
Piper SandlerMaintainedOverweight$42 $44Jul 28, 2026
BarclaysMaintainedOverweight$38 $40May 6, 2026
JP MorganMaintainedOverweight$35 $40Apr 30, 2026
UBSMaintainedBuy$36 $42Apr 30, 2026
Piper SandlerReiteratedOverweight$41 $42Apr 30, 2026
Truist SecuritiesMaintainedBuy$42 $45Apr 30, 2026
B of A SecuritiesMaintainedBuy$38 $42Apr 9, 2026
Piper SandlerReiteratedOverweight$40 $41Mar 4, 2026
Truist SecuritiesMaintainedBuy$38 $42Feb 18, 2026
Goldman SachsMaintainedBuy$36 $45Feb 9, 2026
BarclaysMaintainedOverweight$35 $38Jan 30, 2026
ScotiabankMaintainedSector Outperform$35 $40Jan 29, 2026
Truist SecuritiesMaintainedBuy$36 $38Jan 29, 2026
JefferiesMaintainedBuy$29 $40Jan 6, 2026
Piper SandlerMaintainedOverweight$30 $40Dec 22, 2025
Goldman SachsMaintainedBuy$31 $35Dec 19, 2025
JP MorganMaintainedOverweight$28 $35Dec 16, 2025
B of A SecuritiesMaintainedBuy$29 $32Dec 9, 2025
BarclaysInitiatedOverweight$35Dec 9, 2025
Goldman SachsMaintainedBuy$28 $31Dec 8, 2025
ScotiabankInitiatedSector Outperform$35Dec 5, 2025
JP MorganMaintainedOverweight$26 $28Nov 6, 2025
JP MorganMaintainedOverweight$23 $26Oct 3, 2025

Insider transactions

73 filings from 20 insiders · 10 buy / 11 sell over 6m

Officers and directors of TEVA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
SATCHI-FAINARO RONITDirectorSell415$37.25$15kAug 21, 2026
LIPPMAN EVANOfficerSell18.6k$36.57$680kAug 17, 2026
ZAKS TAL ZVIDirectorSell17$34.87$593Aug 5, 2026
SHIELDS MATTHEWOfficerSell10.0k$32.19$322kJun 18, 2026
ZAKS TAL ZVIDirectorOther14.5k——Jun 5, 2026
SATCHI-FAINARO RONITDirectorOther14.5k——Jun 5, 2026
LICHTENSTEIN CHENDirectorOther14.5k——Jun 5, 2026
SABAG MARKOfficerSell144.2k$34.99$5.05MMay 1, 2026
FOX CHRISTINEOfficerSell21.3k$35.31$751kApr 30, 2026
HUGHES ERIC AOfficerSell9.5k$31.67$302kMar 5, 2026
FOX CHRISTINEOfficerSell7.9k$31.67$251kMar 5, 2026
SHIELDS MATTHEWOfficerSell17.3k$31.67$548kMar 5, 2026
SAVAGE BRIANOfficerSell1.1k$31.67$36kMar 5, 2026
FRANCIS RICHARD DChief Executive OfficerSell20.0k$31.67$634kMar 5, 2026
FRANCIS RICHARD DChief Executive OfficerOther42.5k——Mar 5, 2026
SABAG MARKOfficerOther15.7k——Mar 5, 2026
KALIF ELIYAHU SHARONChief Financial OfficerOther19.9k——Mar 5, 2026
HUGHES ERIC AOfficerOther19.7k——Mar 5, 2026
FOX CHRISTINEOfficerOther17.8k——Mar 5, 2026
SHIELDS MATTHEWOfficerOther17.3k——Mar 5, 2026

Analyst Notes

Sign in to write

No analyst notes on TEVA yet.

Analyst Ratings

10 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current47100Buy1.75
1 mo ago47100Buy1.75
2 mo ago57000Buy1.58
3 mo ago57000Buy1.58
Price target$41.60$33.00 – $50.00
+12.9% to target